Arena Pharmaceuticals, Inc. (ARNA) shares saw a recent bid of $1.39 and 2.9M shares have exchanged hands in the recent trading session, yielding a 6.11% gain over the past week. The stock price increased 2.96% or $-0.04 versus $1.35 at the end of the prior session. This change led market cap to move at $451.08M, putting the price -35.65% below the 52-week high and 23.01% above the 52-week low. The company’s stock has a normal trading capacity of 2.49M shares while the relative volume is 1.16.
To stay one step ahead we extended our research by comparing different price targets. The stock notched a 12-month high of $3.17 while $5.00 target is by far the most aggressive out of analysts who are currently evaluating the company, $1.83 higher than the next highest 52-week price estimate. The lowest 12-month price target for the shares is $2.00, which would be an increase of about 44% of its current value. The mean target of $2.50 should be compared with the price when the stock was languishing around $1.13 a share. And it remains to be seen which target price ARNA can achieve without sacrificing much as the company is holding a -25.67% fall for the past twelve months.
By historical standards, Arena Pharmaceuticals, Inc. remains a cheap stock. The company’s current price-earnings ratio amounts above the average P/E ratio of 150.55 times earnings. For now, Arena Pharmaceuticals, Inc. is the toast of Wall Street as its ABR stands at 2.40 with 1 out of 7 analysts rating the stock a buy. Over the short term, some market observers may have noticed that Arena Pharmaceuticals, Inc. has a 2.39% short float with 15 days to cover. It becomes significant when you consider how many shares are shorted versus the average daily volume, means how many days to cover those short shares at that volume. Arena Pharmaceuticals, Inc. has far performed well this year, with the share price down -2.11% since January. Over the past 2 quarters, the stock is down -0.71%, compared with a fall of nearly -9.15% for 3 months and about 11.20% for the past 30 days.
Revenue for the quarter also did not kill consensus, coming in at $6.62M, compared to the consensus of 8.07M. Nonetheless, from here on out, earnings per share forecasts for the current quarter are $-0.08. The company is expected to report EPS as high as $-0.06 and as low as $-0.11 per share. Similarly, full-year EPS forecasts have ranged between $-0.46 and $-0.28. The mean EPS estimate is $-0.34. On the other side, sales forecasts for the current quarter are $5.43M. The stock is expected to report revenue as high as $8.5M and as low as $3.1M per share. Similarly, full-year sales forecasts have ranged between $18.1M and $32.1M. The mean revenue estimate is $22.78M.
Over the last 5 years, Arena Pharmaceuticals, Inc. has averaged a 35.00% YoY EPS growth rate and a 57.70% revenue growth rate. Analysts are expecting EPS growth rates to be at 79.40% this quarter and EPS estimate for next year reflect -2.90% growth rate.
Sell-side analysts also have something to say about this company. Leerink Partners analysts stated on 19/05/2017 that they launched coverage on this stock with Outperform rating. FBR & Co. analysts stated on 15/09/2016 that they launched coverage on this stock with Outperform rating. RBC Capital Mkts analysts stated on 01/03/2016 that they maintained their Sector Perform rating. RBC Capital Mkts analysts stated on 11/11/2015 that they maintained their Sector Perform rating.